Fortrade Canada Ltd. as an order-execution only dealer is not permitted to provide you with any advice or recommendations. These Market Commentaries should not be construed as a recommendation, advice or any attempt by Fortrade Canada Ltd. to prompt or influence you in making an investment decision to purchase, sell, hold or exchange any security or to influence the timing of such activity. This content is produced by Fortrade Limited which is not registered in any capacity with any securities regulatory authority in Canada.
71% of retail investor accounts lose money when trading CFDs with this provider.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 71% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
70.41% of retail investor accounts lose money when trading CFDs with this provider.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 70.41% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing all your money. Read full risk warning.
US Session Analysis for CFD Instruments 19/03/2021
Fundamental analysis
19 March, 2021
The GER30 and most European stock markets weakened Friday, as a rise in Covid-19 cases and associated lockdowns weighed on recovery hopes. The growth outlook in Europe is weakening as a third wave of Covid-19 infections leads to further mobility restrictions, further delaying the economic recovery. Germany, the largest EU country in terms of population, recorded Thursday the biggest daily rise in confirmed coronavirus cases since Jan. 22. The EU drugs regulator did confirm Thursday that the benefits of AstraZeneca’s Covid-19 vaccine outweighed the risks, but the earlier suspension of the use of this drug by a number of European countries has been another factor slowing what is already a sluggish vaccination rollout across the EU.
